4 Healthcare Stock Stories for Investor Well-Being

Aetna (NYSE:AET): Current price $48.41

Aetna reported on Tuesday that it will divest its Missouri Medicaid unit to WellCare Health Plans as part of its acquisition of Coventry Health Care because their combined Missouri divisions had surpassed Medicaid membership limits. Back in August, Aetna had planned to purchase Coventry for around $5.6 billion so as to grow its Medicaid government health insurance business for the poor and disabled.


Celsion Corporation (NASDAQ:CLSN): Current price $7.79

On Tuesday,  The leading oncology drug development firm Celsion and Zhejiang Hisun Pharmaceutical Company entered into a tech development arrangement for ThermoDox for the greater China region. Through the terms, Hisun will pay $5 million to Celsion at once, while the latter will provide Hisun with support for its ThermoDox manufacturing development program. The payment is non-refundable and is in advance of Celsion’s anticipated reporting of results from its pivotal Phase III trial in hepatocellular carcinoma, also known as primary liver cancer later in January. Zhejiang Hisun is a top Chinese pharmaceutical firm.


Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>

Rexahn Pharmaceuticals (AMEX:RNN): Current price $0.32

Rexahn on Tuesday said that it has named Dr. Peter D. Suzdak as its new Chief Executive, succeeding Dr. Chang Ahn who will move into the position of chief scientist and will also remain as chairman of the board. Rexahn is a clinical stage pharmaceutical firm, developing potential first in class oncology and CNS therapeutics.


Navidea Biopharmaceuticals (NYSE:NAVB): Current price $3.03

Coverage of Navidea shares began at Burrill with a Market Outperform, along with a price target of $5. In a statement, the company commented (in part) that, “Navidea is currently seeking regulatory approval of Lymphoseek, a precision radiopharmaceutical agent used for intraoperative lymphatic mapping, and in our opinion, addresses a $300 MM worldwide market. In addition, the company has in-licensed NAV4694 and NAV5001, which are intended to aid in the diagnosis of Alzheimer’s and Parkinson’s diseases, respectively. All three products address large markets, approaching $1.5 billion worldwide.”


Don’t Miss: These 5 Stocks Beat Earnings 90% of the Time.